NAFDAC: Gabapentinoid Drug Poisoning Alert Issued in Nigeria

• NAFDAC has issued a public alert (No: 039/2026) regarding an increased risk of drug poisoning.
• This risk occurs when gabapentinoids, specifically gabapentin and pregabalin, are used concurrently with opioids and benzodiazepines.
• The warning is based on emerging evidence, a received report, and a study conducted by University College researchers.
• The alert is directed at both healthcare professionals and the public to enhance awareness and prevent adverse outcomes.
• The National Agency for Food and Drug Administration and Control emphasizes the need for careful prescribing and patient education to mitigate these dangers.

This NAFDAC gabapentinoid drug poisoning alert underscores the importance of careful prescribing practices and patient awareness regarding potential drug interactions.

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a critical public alert, designated as Public Alert No: 039/2026, to inform both healthcare professionals and the general public about a significant drug safety concern. This warning highlights an elevated risk of drug poisoning that can occur when specific medications, known as gabapentinoids, are administered concurrently with certain other pharmaceutical agents.

Gabapentinoids, which include the widely prescribed drugs gabapentin and pregabalin, have been identified as posing an increased danger when combined with particular classes of medicines. The alert specifically points to opioids and benzodiazepines as key contributors to this heightened risk of adverse reactions. This NAFDAC gabapentinoid drug poisoning alert underscores the importance of careful prescribing practices and patient awareness regarding potential drug interactions.

The basis for this urgent communication stems from emerging evidence and a report received by the agency, which indicates a clear link between co-administration of these drugs and severe poisoning outcomes. Further substantiating this concern, the alert references a study conducted by researchers at University College, providing a scientific foundation for the regulatory body's proactive stance on this public health issue. This Nigeria drug interaction warning serves as a vital update for all stakeholders in the healthcare ecosystem.

As the primary regulatory body responsible for safeguarding public health through the control and supervision of food, drugs, cosmetics, medical devices, packaged water, and chemicals, NAFDAC's role in issuing such alerts is paramount. The National Agency for Food and Drug Administration and Control is mandated to monitor drug safety post-market approval, and alerts like this one are a direct fulfillment of that responsibility. The agency's proactive communication aims to prevent harm by disseminating crucial information gleaned from ongoing surveillance and scientific research.

This NAFDAC public health warning emphasizes the continuous need for vigilance within the pharmaceutical sector and among medical practitioners. Pharmaceutical companies are implicitly urged to review their product information and labeling for gabapentin and pregabalin, ensuring that potential interactions with opioids and benzodiazepines are clearly communicated. Healthcare providers, in turn, are expected to integrate this new information into their prescribing decisions, particularly when managing patients who may require treatment with multiple medications.

The alert reflects NAFDAC's commitment to ensuring the safe use of medicines and mitigating risks associated with drug interactions. It serves as a reminder that even approved drugs can pose significant dangers when used improperly or in combination with other substances, highlighting the dynamic nature of drug safety surveillance and the importance of adapting clinical practices based on new evidence.

The potential for drug poisoning from gabapentinoid co-administration with opioids and benzodiazepines carries serious implications for patient safety. The gabapentin and pregabalin risk, when combined with these central nervous system depressants, can lead to severe respiratory depression, profound sedation, coma, and even death. This makes the NAFDAC gabapentinoid drug poisoning alert a critical piece of information for anyone involved in patient care or medication management.

Patients who are currently prescribed gabapentinoids alongside opioids or benzodiazepines should be made aware of this increased drug poisoning risk gabapentinoids present. Healthcare professionals must engage in thorough medication reconciliation and patient education, ensuring that individuals understand the dangers of concurrent use and are advised on how to recognize symptoms of overdose or adverse reactions. The opioids benzodiazepines interaction NAFDAC has highlighted requires immediate attention to prevent potentially fatal outcomes.

Ultimately, this alert reinforces the need for a collaborative approach to medication safety, involving prescribers, pharmacists, and patients. It underscores that while these medications serve important therapeutic purposes, their combined use demands extreme caution and careful monitoring to prevent serious harm. The ongoing evaluation of drug safety by regulatory bodies like NAFDAC is essential for protecting public health and ensuring that the benefits of medicines continue to outweigh their risks.

Pharmaceutical companies and healthcare providers in Nigeria must review drug labeling, prescribing guidelines, and patient information to mitigate liability risks associated with gabapentinoid co-prescription. Compliance officers should update internal protocols to reflect NAFDAC's warning and ensure adherence to new safety standards.

Source: Original reporting via NAFDAC Public Alert No: 039/2026